Edition:
United Kingdom

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

170.41USD
12 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$170.41
Open
$171.00
Day's High
$171.00
Day's Low
$167.91
Volume
351,157
Avg. Vol
276,627
52-wk High
$182.36
52-wk Low
$123.73

Latest Key Developments (Source: Significant Developments)

Shire Says Receives Approval Of Firazyr In Japan
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Shire PLC ::SHIRE RECEIVES APPROVAL OF FIRAZYR® (ICATIBANT INJECTION) FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA (HAE) ATTACKS IN JAPAN.SHIRE PLC - STUDY SHOWED THAT FIRAZYR WAS WELL TOLERATED AND DEMONSTRATED SYMPTOM RELIEF DURING AN ACUTE HAE ATTACK THROUGH A SINGLE INJECTION.  Full Article

Takeda Is Said To Weigh Sale Of Shire Eye Care Drug To Cut Debt - Bloomberg
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - :TAKEDA IS SAID TO WEIGH SALE OF SHIRE EYE CARE DRUG TO CUT DEBT - BLOOMBERG, CITING SOURCES.  Full Article

Shire Announces Tender Offer For Up To $2.25 Bln Outstanding Notes
Friday, 24 Aug 2018 

Aug 24 (Reuters) - Shire PLC ::ANNOUNCES CASH TENDER OFFERS FOR UP TO $2,250,000,000 OUTSTANDING PRINCIPAL AMOUNT OF NOTES.COMMENCED CASH TENDER OFFERS TO PURCHASE UP TO $2.25 BILLION OF BAXALTA'S OUTSTANDING 2.875% SENIOR NOTES DUE 2020, AMONG OTHERS.  Full Article

FDA approves potential blockbuster drug from Shire for rare swelling disorder
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - U.S. Food And Drug Administration: :U.S. FDA - APPROVED TAKHZYRO, FIRST MONOCLONAL ANTIBODY APPROVED IN U.S. TO TREAT PATIENTS 12 YRS & OLDER WITH TYPES I AND II HEREDITARY ANGIOEDEMA.  Full Article

Takeda Pharmaceutical Announces Statement Regarding US FTC Clearance
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Takeda Pharmaceutical Company Ltd <4502.T>::STATEMENT REGARDING US FTC CLEARANCE.TAKEDA RECEIVES CLEARANCE FROM UNITED STATES FEDERAL TRADE COMMISSION FOR PROPOSED ACQUISITION OF SHIRE PLC.  Full Article

EMA Recommendations For June 2018
Friday, 29 Jun 2018 

June 29 (Reuters) - EU Medicines Agency::EMA RECOMMENDATIONS FOR JUNE 2018.EMA RECOMMENDS APPROVAL OF NOVARTIS GENE-BASED CELL THERAPY KYMRIAH.EMA RECOMMENDS APPROVAL OF BAXALTA' INNOVATIONS' DRUG FOR VON WILLEBRAND DISEASE VONICOG ALFA.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF ULTRAGENYX DRUG FOR TREATMENT OF SLY SYNDROME.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF GILEAD SCIENCES' CAR-T TREATMENT FOR ADVANCED NON-HODGKIN LYMPHOMA YESCARTA.  Full Article

Takeda Pharm CEO Weber Says Neuroscience Will Continue To Be A Core Area
Tuesday, 8 May 2018 

May 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T> Chief Executive Officer Christophe Weber::NEUROSCIENCE WILL CONTINUE TO BE A CORE AREA.JOBS COULD BE IMPACTED.  Full Article

GSK New R&D Head Barron Says Work To Do To Translate DPU Research Into Drugs
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Glaxosmithkline ::NEW RESEARCH AND DEVELOPMENT HEAD BARRON SAYS WORK TO DO TO TRANSLATE RESEARCH AT DPU UNITS INTO DRUGS.  Full Article

GSK Expecting Shingrix Sales For Year To Be Above 400 Million Stg
Wednesday, 25 Apr 2018 

April 25 (Reuters) - GlaxoSmithKline ::CFO SAYS EXPECTING SHINGRIX SALES FOR YEAR TO BE AT THE SAME RATE AS IN Q1, OR 400 MILLION STG+ FOR 2018.  Full Article

Takeda Says Notes Statement By Shire Regarding Revised Proposal, Deadline Extension
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd <4502.T>::SAYS NOTES STATEMENT BY SHIRE PLC REGARDING REVISED PROPOSAL AND EXTENSION OF PUSU DEADLINE TO MAY 8, 2018.SAYS INTENDS TO MAINTAIN ITS WELL-ESTABLISHED DIVIDEND POLICY AND INVESTMENT GRADE CREDIT RATING.  Full Article

Britain's FTSE relatively stable as Brexit impasse has mixed impact

MILAN, Oct 15 Britain's top share index was steady on Monday as a deadlock in Brexit talks depressed domestic stocks but helped internationally focused companies as it weakened the pound.